Aamorb Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.40 M
- Paid Up Capital ₹ 2.00 M
- Company Age 18 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1.50 Cr
- Revenue Growth -5.81%
- Profit Growth -19.41%
- Ebitda -15.75%
- Net Worth 4.34%
- Total Assets 13.86%
About Aamorb Pharmaceuticals
Aamorb Pharmaceuticals Private Limited (APPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 29 March 2006 and has a history of 18 years and ten months. Its registered office is in Indore, Madhya Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.40 M and a paid-up capital of Rs 2.00 M.
The company has closed loans amounting to ₹1.50 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Tanishq Jaswani and Mahesh Jaswani serve as directors at the Company.
Company Details
-
Location
Indore, Madhya Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U02423MP2006PTC018519
-
Company No.
018519
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
29 Mar 2006
-
Date of AGM
15 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Gwalior
Industry
What products or services does Aamorb Pharmaceuticals Private Limited offer?
Aamorb Pharmaceuticals Private Limited offers a wide range of products and services, including Nutritional Drinks, For Adults, Health Conditions, Menopause.
Who are the key members and board of directors at Aamorb Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mahesh Jaswani
|
Director | 29-Mar-2006 | Current |
|
Tanishq Jaswani
|
Director | Current |
Financial Performance of Aamorb Pharmaceuticals.
Aamorb Pharmaceuticals Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 5.81% decrease. The company also saw a substantial fall in profitability, with a 19.41% decrease in profit. The company's net worth moved up by a moderate rise of 4.34%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aamorb Pharmaceuticals?
In 2023, Aamorb Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹15.00 M
Charges Breakdown by Lending Institutions
- State Bank Of India : 1.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Jun 2006 | State Bank Of India | ₹1.50 Cr | Satisfied |
How Many Employees Work at Aamorb Pharmaceuticals?
Unlock and access historical data on people associated with Aamorb Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aamorb Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aamorb Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
